You are here: Home: PCU 3 | 2006: Mario A Eisenberger, MD: Select publications

SELECT PUBLICATIONS

Carducci MA. What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer? J Clin Oncol 2005;23:3304-7. Abstract

Eisenberger MA et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostate carcinoma. J Clin Oncol 1985;3(6):827-41. Abstract

Goodin S et al. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol 2005;23:3352-7. Abstract

Hruska PP et al. The role of primary chemotherapy for prostate cancer: Has the time come? Curr Urol Rep 2006;7(3):233-8. Abstract

Kattan MW et al. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-507. Abstract

Kattan MW et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71. Abstract

Messing EM et al. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472-9. Abstract

Messing EM et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341(24):1781-8. Abstract

Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. Abstract

Rosenbaum E et al. Adjuvant weekly docetaxel for high-risk prostate cancer patients following radical prostatectomy. Proc ASCO 2006;Abstract 84.

Rosenbaum E et al. A pilot multicenter phase II study of adjuvant docetaxel for high risk prostate cancer patients after radical prostatectomy: Preliminary data. Proc ASCO 2005;Abstract 4565.

Rosenbaum E et al. Adjuvant weekly docetaxel for high-risk prostate cancer patients after radical prostatectomy: Preliminary data of a multicenter pilot trial. Proc ASCO 2004;Abstract 4649.

Tannock IF et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract

Walczak JR, Carducci MA. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: An Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study. Urology 2003;62(Suppl 1):141-6. Abstract

Home